



Investor and Media Contact:

Michelle Edwards, Investor Relations

medwards@oxigene.com

650-635-7006

OXiGENE Announces Clinical Data from FACT Study to be Presented at the 14th International Thyroid Congress

SOUTH SAN FRANCISCO, Calif., Jun 23, 2010 -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from its clinical trials of ZYBRESTAT and chemotherapy in patients with anaplastic thyroid cancer (ATC), will be presented at the upcoming 14th International Thyroid Congress in Paris, France on September 12, 2010. OXiGENE will release a summary of results immediately after they are presented.

ZYBRESTAT Presentation Details:

Oral Presentation Title: RANDOMIZED PHASE 2/3 TRIAL OF A TUMOR VASCULAR DISRUPTING AGENT FOSBRETABULIN TROMETHAMINE (CA4P) WITH CARBOPLATIN (C), AND PACLITAXEL (P) IN ANAPLASTIC THYROID CANCER (ATC): INTERIM SAFETY AND EFFICACY RESULTS OF THE FACT TRIAL

Presenter: Rossella Elisei, M.D.

Session Title: Prospective trials in refractory thyroid cancers

Date : Sunday 12 Sept.

Time of session : 14:45 - 16:15

Location: Room Bordeaux - level 3

About ZYBRESTAT (fosbretabulin)

ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-squamous non-small cell lung cancer and other clinical trials. OXiGENE believes that ZYBRESTAT is poised to become an important product in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include projected study outcomes, emerging oncology treatments and the expected conclusion of ongoing or initiation of new clinical studies may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the outcome of clinical studies and the availability of additional financing to continue development of ZYBRESTAT. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2009.

###